Fiche du document
- doi: 10.1158/2159-8290.CD-21-0003
- issn: 2159-8274
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1158/2159-8290.CD-21-0003
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34479871
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2159-8290
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_D82928F3BB2B5
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Tumours Neoplasms Therapeutic immunologyCiter ce document
F.G. Herrera et al., « Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. », Serveur académique Lausannois, ID : 10.1158/2159-8290.CD-21-0003
Métriques
Partage / Export
Résumé
Developing strategies to inflame tumors is critical for increasing response to immunotherapy. Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell infiltration and enables responsiveness to combinatorial immunotherapy in an IFN-dependent manner. Treatment efficacy relied upon mobilizing both adaptive and innate immunity and depended on both cytotoxic CD4 + and CD8 + T cells. LDRT elicited predominantly CD4 + cells with features of exhausted effector cytotoxic cells, with a subset expressing NKG2D and exhibiting proliferative capacity, as well as a unique subset of activated dendritic cells expressing the NKG2D ligand RAE1. We translated these findings to a phase I clinical trial administering LDRT, low-dose cyclophosphamide, and immune checkpoint blockade to patients with immune-desert tumors. In responsive patients, the combinatorial treatment triggered T-cell infiltration, predominantly of CD4 + cells with Th1 signatures. Our data support the rational combination of LDRT with immunotherapy for effectively treating low T cell-infiltrated tumors. SIGNIFICANCE: Low-dose radiation reprogrammed the tumor microenvironment of tumors with scarce immune infiltration and together with immunotherapy induced simultaneous mobilization of innate and adaptive immunity, predominantly CD4 + effector T cells, to achieve tumor control dependent on NKG2D. The combination induced important responses in patients with metastatic immune-cold tumors.This article is highlighted in the In This Issue feature, p. 1.